《Nature,2月24日,Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2021-02-25
  • Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19
    Francisco J. Salguero, Andrew D. White, […]Miles W. Carroll
    Nature Communications volume 12, Article number: 1260 (2021)

    Abstract
    A novel coronavirus, SARS-CoV-2, has been identified as the causative agent of the current COVID-19 pandemic. Animal models, and in particular non-human primates, are essential to understand the pathogenesis of emerging diseases and to assess the safety and efficacy of novel vaccines and therapeutics. Here, we show that SARS-CoV-2 replicates in the upper and lower respiratory tract and causes pulmonary lesions in both rhesus and cynomolgus macaques. Immune responses against SARS-CoV-2 are also similar in both species and equivalent to those reported in milder infections and convalescent human patients. This finding is reiterated by our transcriptional analysis of respiratory samples revealing the global response to infection. We describe a new method for lung histopathology scoring that will provide a metric to enable clearer decision making for this key endpoint. In contrast to prior publications, in which rhesus are accepted to be the preferred study species, we provide convincing evidence that both macaque species authentically represent mild to moderate forms of COVID-19 observed in the majority of the human population and both species should be used to evaluate the safety and efficacy of interventions against SARS-CoV-2. Importantly, accessing cynomolgus macaques will greatly alleviate the pressures on current rhesus stocks.

  • 原文来源:https://www.nature.com/articles/s41467-021-21389-9
相关报告
  • 《Nature,6月9日,Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-06-10
    • Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 Brandi N. Williamson, Friederike Feldmann, Benjamin Schwarz, Kimberly Meade-White, Danielle P. Porter, Jonathan Schulz, Neeltje van Doremalen, Ian Leighton, Claude Kwe Yinda, Lizzette Pérez-Pérez, Atsushi Okumura, Jamie Lovaglio, Patrick W. Hanley, Greg Saturday, Catharine M. Bosio, Sarah Anzick, Kent Barbian, Tomas Cihlar, Craig Martens, Dana P. Scott, Vincent J. Munster & Emmie de Wit Nature (2020) Abstract Effective therapeutics to treat COVID-19 are urgently needed. While many investigational, approved, and repurposed drugs have been suggested, preclinical data from animal models can guide the search for effective treatments by ruling out treatments without in vivo efficacy. Remdesivir (GS-5734) is a nucleotide analog prodrug with broad antiviral activity1,2, that is currently investigated in COVID-19 clinical trials and recently received Emergency Use Authorization from the US Food and Drug Administration3,4. In animal models, remdesivir treatment was effective against MERS-CoV and SARS-CoV infection.2,5,6 In vitro, remdesivir inhibited replication of SARS-CoV-2.7,8 Here, we investigated the efficacy of remdesivir treatment in a rhesus macaque model of SARS-CoV-2 infection9. In contrast to vehicle-treated animals, animals treated with remdesivir did not show signs of respiratory disease and had reduced pulmonary infiltrates on radiographs and reduced virus titers in bronchoalveolar lavages 12hrs after the first treatment administration. Virus shedding from the upper respiratory tract was not reduced by remdesivir treatment.
  • 《2月24日_恒河猴和食蟹猴作为COVID-19感染模型的比较》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2021-02-25
    • Nature Communications 于2月24日发表了英格兰公共卫生局和牛津大学等的文章“Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19”,文章描述了恒河猴和食蟹猴作为COVID-19感染模型的比较。 文章称,动物模型,特别是非人类灵长类动物模型,对于理解新发疾病的发病机制以及评估新疫苗和治疗方法的安全性和有效性至关重要。研究发现SARS-CoV-2在恒河猴和食蟹猴的上呼吸道和下呼吸道复制,并导致肺部病变。在这两个物种中,针对SARS-CoV-2的免疫反应也相似,相当于在轻度感染和恢复期人类患者中报道的免疫反应。研究人员对呼吸道样本的转录分析重申了这一发现,揭示了对感染的整体反应。该研究描述了一种新的肺组织病理学评分方法,该方法将提供一个指标,使针对此关键终点的决策更加清晰。与之前的出版物(以恒河猴为首选研究物种)相比,该研究提供了令人信服的证据,即两种猕猴中的疾病反应确实代表了在大多数人口中观察到的轻度至中度形式的COVID-19,因此应同时使用两个物种评估针对SARS-CoV-2的干预措施的安全性和有效性。重要的是,获取食蟹猴将极大地缓解目前恒河猴种群的压力。 原文链接:https://www.nature.com/articles/s41467-021-21389-9